ENDRA Life Sciences Inc. - Common Stock (NDRA)

Active Stocks Releasing News Recently to Watch Now: Myseum, Inc. (NASDAQ: MYSE ), SurgePays, Inc. (NASDAQ: SURG ), ENDRA Life Sciences (NASDAQ: NDRA ), Scienjoy Corp (NASDAQ: SJ ), Roadzen Inc (NASDAQ: RZDN ), Kartoon Studios, Inc (NYSE: TOON ), Power Metallic Mines (TSX-V: PNPN | OTCQB: PNPNF ), Synergy CHC Corp. (NASDAQ: SNYR ), Datavault AI (NASDAQ: DVLT ) and Peraso Inc (NASDAQ: PRSO ) — all active in trading sessions and should be added to your radar now as momentum accelerates across the small-cap biotech, tech, media and AI sectors.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS’ thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%.

ENDRA Life Sciences (NASDAQ: NDRA), the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®) liver imaging technology, is highlighting a powerful new financial engine built through its alignment with the Arca U.S. Treasury Fund (ARCU) . The partnership provides ENDRA with an institutional framework to generate reliable yield, preserve capital, and reinvest strategically—strengthening the Company’s long-term capacity to advance breakthrough medical innovation.

Datavault AI Inc. (NASDAQ: DVLT), a leader in AI-powered data experience, valuation, and monetization, today announced an exclusive licensing agreement with Wellgistics Health Inc. (NASDAQ: WGRX) for the integration of Datavault’s proprietary blockchain-enabled smart-contract patent portfolio. The strategic deal positions Wellgistics to emerge as a Web 3.0 health-information transfer leader across the $634 billion U.S. prescription drug market .

ENDRA Life Sciences (NASDAQ: NDRA) is drawing renewed attention from investors with the rollout of its “Yield-to-Innovation” strategy, a financial and operational framework designed to strengthen long-term growth while advancing the Company’s breakthrough TAEUS® liver imaging technology.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction-associated liver disease (“MASLD”) and metabolic dysfunction-associated steatohepatitis (“MASH”), today announces encouraging preliminary results from a single-site clinical feasibility study evaluating its improved TAEUS Liver device for quantifying liver fat fraction, which is a key biomarker of steatotic liver disease (“SLD”).

ENDRA Life Sciences (NASDAQ: NDRA), a pioneer in next-generation medical imaging for the early detection and monitoring of liver disease, is redefining strategic finance for public companies through an innovative treasury management program that enhances liquidity, financial stability, and long-term growth potential. By combining disciplined capital management with breakthroughs in health technology, ENDRA is creating a model that strengthens its balance sheet while accelerating the development of its TAEUS® platform—positioning the Company for expanded market visibility and clinical leadership.

ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today provided a business update and reported financial results for the three and nine months ended September 30, 2025.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer in medical imaging and digital innovation, is redefining the intersection of healthcare technology and decentralized finance through its groundbreaking Thermo Acoustic Enhanced UltraSound (TAEUS®) platform and its newly launched Digital Asset Treasury (DAT) strategy. Together, these initiatives position ENDRA as one of the most forward-looking companies in both the medtech and blockchain arenas.

ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today announced a significant step in its digital asset strategy with the commencement of staking its holdings of HYPE, the native token of the Hyperliquid ecosystem.

The Viral Threat Hiding in Plain Sight: Between August 2024 and July 2025, the CDC’s NoroSTAT system recorded 2,675 norovirus outbreaks across the United States. A genetic shift has emerged: the GII.17 strain has overtaken the long-dominant GII.4 lineage , now responsible for roughly 75 percent of reported cases . Health officials warn this strain replacement increases outbreak frequency and severity, as current cleaning and immunity defenses are quickly becoming outdated. Why It Matters

ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), has successfully closed its previously announced private investment in public equity ("PIPE") financing led by institutional and cryptocurrency investors.

ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today announced an aggregate of $4.9 million in commitments for a private placement (the “Offering”) led by leading institutional and cryptocurrency investors. The proceeds will be used to launch a digital asset treasury (“DAT”) strategy directed at the highest conviction holdings of Arca Investment Management, LLC (“Arca”) in the DeFi sector, beginning with the cryptocurrencies of the pioneering decentralized exchanges and protocols, with a focus on perpetual futures such as HYPE.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three and six months ended June 30, 2025.

Investor interest builds in speculative micro-cap names under the radar of Wall Street's "Magnificent Seven" ENDRA

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer in imaging technologies for the early detection and monitoring of metabolic liver disease, today announced that its ongoing multisite pilot study has helped to identify several product enhancements to further improve the performance of its TAEUS® Liver system against the gold standard, MRI. These findings are expected to drive substantial improvements to the device’s probe design and proprietary algorithms, measurably improving diagnostic accuracy and repeatability. These enhancements are currently being implemented and are expected to strengthen the outcomes of the Company’s planned U.S. Food and Drug Administration (“FDA”) De Novo pivotal study.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three months ended March 31, 2025.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs and other metabolic dysfunction-associated steatohepatitis (MASH) therapies.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC (“Nasdaq”).

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a poster titled “Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity” for presentation at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Disease (AASLD), taking place November 15-19 in San Diego.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office has issued to ENDRA a new patent EP4247282 (the ‘282 patent) titled “Method and System for Monitoring Tissue Temperature.”

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the activation of a post market clinical study and first patient scanned with the TAEUS liver system at LMU University Hospital in Munich, one of the leading medical research centers in Europe.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that on August 27, 2024, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for an extension through November 20, 2024, to evidence compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market.